You searched for "disease"

2385 results found

It’s not all about ARED - Time for a pragmatic approach to nutrition for eye health?

Advances in treatment for retinal diseases involving neovascularisation have undoubtedly changed the future of eye care across the UK for the better, but also created great challenges for service delivery in ophthalmology, particularly within the NHS. Some statistics are starting...

Assessing everyday visual function in dry AMD – what matters to the person?

Age-related macular degeneration (AMD) is the primary cause of blindness in the developed world and is accountable for more than one half of sight impairment registrations within England and Wales [1]. AMD is prevalent in people aged 60 years and...

Glaukos Launches iStent infinite® in the UK Following MDR Approval

Glaukos has announced the launch of its latest glaucoma treatment, iStent infinite®, in the UK market after securing approval under the European Medical Device Regulation (MDR). This new approval process is rigorous and provides ophthalmologists with reassurance regarding the efficacy...

Outcomes in intermediate age-related macular degeneration (AMD): A MACUSTAR study report

Intermediate AMD (iAMD) is the most high-risk AMD stage for progressing to late AMD. This article gives the report of the MACUSTAR study. A wide range of assessments were conducted across 20 sites in seven European countries, in accordance with...

Working smarter not harder: How to transform eyecare delivery in the United Kingdom (part 2)

Are we doing enough to meet the current demands on ophthalmic services? In part two of a two-part series (see Part 1 here), Rosalind Harrison explains how efficiency can be improved by setting up eye services in community hubs. The...

Conjunctival mapping biopsies in sebaceous carcinoma

This is a retrospective review of conjunctival mapping biopsies in patients with periocular sebaceous cell carcinoma. The authors reviewed the biopsy technique and outcomes of 45 patients who had mapping biopsies performed over a 25-year period. A total of 429...

Role of fundus autofluorescence patterns and baseline atrophy area on geographic atrophy progression

Central geographic atrophy (GA) is one of the morphological sub types of late-stage macular degeneration. The natural course of the disease is characterised by expanding areas of macular atrophy, which cause absolute scotoma. Fundus autofluorescence (FAF) is derived from lipofuscin...

The prevalence of macular cysts in patients with clinical cone-rod dystrophy determined by spectral domain optical coherence tomography

Cone-rod dystrophy is a progressive photoreceptor disorder which has multiple inheritance patterns. It is rare, with a prevalence of 1 in 40,000. Macular cysts are well recognised in other photoreceptor conditions such as retinitis pigments and choroideraemia, while they are...

Viral uveitis

This review covers viral causes of anterior uveitis. A viral aetiology should be suspected when anterior uveitis is accompanied by ocular hypertension, diffuse stellate keratic precipitates or the presence of iris atrophy. Most common viruses associated are herpes simplex, varicella-zoster...

Treatment for chronic severe bilateral blepharokeratoconjunctivitis

This study evaluated the efficacy and safety of oral azithromycin treatment combined with topical antibiotics and anti-inflammatory agents in paediatric patients with chronic severe bilateral blepharokeratoconjunctivitis (BKC). The authors recruited 29 consecutive patients (58 eyes) with mean age at diagnosis...

Report on ‘2024: Artificial Intelligence and the Eye’

As the application of artificial intelligence (AI) is brought to the foray of clinical medicine, you can be forgiven for thinking that it is a relatively recent technology. However, researchers and computer scientists have been working on it for many...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...